Antibodies and methods for PTK7 detection
By providing PTK7 binding agents with specific amino acid sequences, the problem of slow antibody construction in existing technologies has been solved, enabling efficient detection of PTK7-positive cells and cancer diagnosis, and providing reliable IHC kits to support early diagnosis and treatment of diseases.
Patent Information
- Application Number
- CN202480074945.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-11-27
- Filing Date
- 2024-11-27
- Publication Date
- 2026-06-23
AI Technical Summary
The construction of effective PTK7 antibodies in existing technologies is slow and difficult to use for the detection of PTK7-positive cells and cancer diagnosis, and there is a lack of reliable IHC kits.
Protein tyrosine kinase 7 (PTK7) binders, including antibodies comprising heavy chain variable regions and light chain variable regions of specific amino acid sequences, are provided for the detection of PTK7-positive cells. The binders may contain heavy chain constant regions and light chain constant regions, and PTK7 expression in cells and tissues is analyzed by detecting the formation of the binding complex.
This technology enables efficient detection of PTK7-positive cells, improves the specificity and sensitivity of cancer diagnosis, provides a reliable IHC kit for cancer detection, and supports early diagnosis and treatment decisions.